Implementation of pathogen reduced cryoprecipitate for surgical services: A retrospective review of blood product utilization and fibrinogen repletion

After the implementation of prCFC, we observed a decreased plasma fibrinogen increment per product transfused. However, there was no impact on the utilization of blood products and the time to cryoprecipitated blood product transfusion decreased. The results reinforce previously published reductions in turnaround time while uniquely assessing the time from order to transfusion. While fibrinogen increments were reduced post-implementation, this difference may not be clinically significant as there were no overall changes in perioperative transfusion of blood components.